This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-12 and is reviewed periodically as new material appears.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
=== Return to the Republic === Shortly after the end of the Provisional Government, in 1910, formal relations between Cuba and Spain were resumed. In October 1912, the Grand Commander of the Supreme Council, Manuel S. Castellanos, and the Freemason Luther S. Harvey, travelled to Washington, D.C., to attend the International Conference of Supreme Councils. During the runup to the 1912 Cuban general election, the Lodges of Cuba were once again subjected to internal divisions motivated by the political reality. That year, José Fernández Pellón Castellanos and the Jurisprudence Commission released a statement which the Grand Lodge, and Freemasonry, specifically forbade the practice of politics in the Lodge. At the same time, Grand Master Francisco Sánchez Curbelo was in the election to become a representative in the Cuban House of Representatives, and in an issue of La Gran Logia, Aurelio Miranda tacitly expressed his desire that Freemasons should vote for him. At the quarterly meeting of the High Chamber of the Grand Lodge of Cuba, the President of the High Chamber, Valdés Codina presided over a proposal: "To recommend to all the lodges of the obedience, so that they in turn may recommend to the members of all their columns, the supreme convenience of each one casting his vote for the masons who are nominated, whatever the party or group that nominates him." In a public response to the calls to elect Grand Master Francisco Sánchez Curbelo, he replied: "...It is necessary to Respect everyone, listen to everyone,...
==== Biofilm management ==== We are developing greater insight into the association between delayed healing and the presence of biofilm. The relationship between delayed healing and the need for debridement is also being acknowledged. It has been suggested that the presence of wound slough provides an indication of biofilm presence, therefore, indicating the need to reduce the wound bioburden. Methods of effectively managing wound biofilms have been reported and include the use of topical agents, systemic antibiotics and regular episodes of debridement. Despite these advances it has been recognised that indiscriminate and widespread use of antibiotics both inside and outside of medicine is playing a substantial role in the emergence of bacterial resistance. On a more positive note, antiseptics have been reported to possess a clear cut role in the control of wound bioburden where there are indications or risk of infection.
Sugar cane accounted for around 21% of the global crop production over the 2000–2021 period. The Americas was the leading region in the production of sugar cane (52% of the world total). Global production of sugarcane in 2022 was 1.9 billion tonnes, with Brazil producing 38% of the world total and India 23% (table). Sugarcane is any of several species, or their hybrids, of giant grasses in the genus Saccharum in the family Poaceae. They have been cultivated in tropical climates in the Indian subcontinent and Southeast Asia over centuries for the sucrose found in their stems.
When sapiens began to expand and spread, he eliminated the other contemporary races [including Neanderthals] just as the white man drove out the Australian aborigines and the North American Indians. In general, the extinction of Neanderthals is ascribed predominantly to competition with modern humans. The success of modern humans over Neanderthals is usually attributed to a higher birth rate and population, facilitated by better long-distance mobility and more complex technologies and subsistence strategies. Some Neanderthal populations may have also been assimilated into modern human populations rather than being ecologically outcompeted. Assimilation had long been hypothesised with supposed hybrid specimens, and was revitalised with the discovery of archaic human DNA in modern humans. Similarly, the Châtelperronian industry of central France and northern Spain may represent a culture of Neanderthals adopting modern human techniques, via acculturation. Other ambiguous transitional cultures include the Italian Uluzzian industry, and the Central European Szeletian industry. Neanderthal extinction has also been ascribed to their low population as well as the resulting mutational meltdown, making them less adaptable to major environmental changes or new diseases introduced by immigrating modern humans. It is unclear if climatic degradation would have severely impacted Neanderthals given how many glacial periods they persisted through in Europe.
=== Overview === Weather forecasts during CAD events are especially prone to inaccuracies. Precipitation type and daily high temperatures are especially difficult to predict. Numerical weather models tend to be more accurate in predicting the development of a CAD event, and less accurate in predicting their erosion. Manual forecasting can provide more accurate forecasts. An experienced human forecaster will use numerical models as a guide, but account for the model's inaccuracies and shortcomings.
Sources: en.wikipedia.org
=== Chimeric and humanized === To reduce murine antibody immunogenicity (attacks by the immune system against the antibody), murine molecules were engineered to remove immunogenic content and to increase immunologic efficiency. This was initially achieved by the production of chimeric (suffix -ximab) and humanized antibodies (suffix -zumab). Chimeric antibodies are composed of murine variable regions fused onto human constant regions. Taking human gene sequences from the kappa light chain and the IgG1 heavy chain results in antibodies that are approximately 65-75% human. This reduces immunogenicity, and thus increases serum half-life as the chimeric or humanized antibody is less likely to be recognized as foreign by the bodies immune system. Humanised antibodies are produced by grafting murine hypervariable regions on amino acid domains into human antibodies. This results in a molecule of approximately 95% human origin. Humanised antibodies bind antigen much more weakly than the parent murine monoclonal antibody, with reported decreases in affinity of up to several hundredfold. Increases in antibody-antigen binding strength have been achieved by introducing mutations into the complementarity determining regions (CDR), using techniques such as chain-shuffling, randomization of complementarity-determining regions and antibodies with mutations within the variable regions induced by error-prone PCR, E. coli mutator strains and site-specific mutagenesis.
=== Specific diseases === A common cause for hyperprolactinemia is prolactinomas and other tumors arising near the pituitary. These adjacent tumors, such as those that cause acromegaly, can physically compress the pituitary stalk and block the flow of dopamine from the hypothalamus to the pituitary gland, causing prolactin levels to increase. Other causes include chronic kidney failure, hypothyroidism, liver cirrhosis, bronchogenic carcinoma and sarcoidosis. Hyperprolactinemia develops in one-third of individuals with chronic kidney disease due to impaired renal clearance and regulation. Some women with polyendocrine metabolic ovarian syndrome may have mildly elevated prolactin levels. Premenstrual dysphoric disorder appears to be also correlated with elevated prolactin levels. In men, hyperprolactinemia leads to hypoactive sexual desire and, occasionally, erectile dysfunction. However, the link between erectile dysfunction and prolactin levels is not conclusive. When prolactin levels return to normal in these individuals, sexual desire fully recovers; however, erectile dysfunction only partially recovers. Nonpuerperal mastitis may induce transient hyperprolactinemia (neurogenic hyperprolactinemia) of about three weeks' duration; conversely, hyperprolactinemia may contribute to nonpuerperal mastitis. Some inflammatory conditions, such as rheumatoid arthritis and systemic lupus erythematosus, are also linked to higher prolactin levels in certain regions.
=== Discovery of radioactive recoil === Harriet Brooks observed a radioactive recoil in 1904, but interpreted it wrongly. Hahn and Meitner succeeded in demonstrating the radioactive recoil incident to alpha particle emission and interpreted it correctly. Hahn pursued a report by Stefan Meyer and Egon Schweidler of a decay product of actinium with a half-life of about 11.8 days. Hahn determined that it was actinium X (radium-223). He also discovered that at the moment when a radioactinium (thorium-227) atom emits an alpha particle, it does so with great force, and the actinium X experiences a recoil. This is enough to free it from chemical bonds, and it has a positive charge, and can be collected at a negative electrode. Hahn was thinking only of actinium, but on reading his paper, Meitner told him that he had found a new way of detecting radioactive substances. They set up some tests, and soon found actinium C'' (thallium-207) and thorium C'' (thallium-208). The physicist Walther Gerlach described radioactive recoil as "a profoundly significant discovery in physics with far-reaching consequences".
Pitting also may be caused by a variety of systemic diseases, including reactive arthritis and other connective tissue disorders, sarcoidosis, pemphigus, alopecia areata, and incontinentia pigmenti. Because pitting is caused by defective layering of the superficial nail plate by the proximal nail matrix, any localized dermatitis (e.g., atopic dermatitis or chemical dermatitis) that disrupts orderly growth in that area also can cause pitting.
Dry beriberi especially affects the peripheral nervous system. Wet beriberi especially affects the cardiovascular system and other bodily systems. Infantile beriberi affects the babies of malnourished mothers. Gastrointestinal beriberi affects the digestive system and other bodily systems.
Sources: en.wikipedia.org
Willes (1963), former president of the Federal Reserve Bank of Minneapolis, CEO and Publisher of Los Angeles Times and Deseret Management Corporation Harry Saal (1963), co-founder of Network General Corporation, developer of the Sniffer Steven Clifford (1964), former CEO of King Broadcasting Company and National Mobile Television Arthur Cutler (1965), restaurateur, founder of Carmine's, Ollie's, and owner of Murray's Sturgeon Shop Ed Goodgold (1965), music industry executive and former manager of Sha Na Na, coined the term "trivia" Michael Gould (1966), former CEO of Bloomingdale's Julian Geiger (1967), former CEO of Aéropostale and current CEO of Crumbs Bake Shop Richard Sackler (1967), billionaire chairman and president of Purdue Pharma known for the development of Oxycontin Denny Greene (1971), former executive at Columbia Pictures, professor at University of Dayton School of Law, and member of Sha Na Na Mark E. Kingdon (1971), hedge fund manager, president of Kingdon Capital Management Philip L. Milstein (1971), former chairman and CEO of Emigrant Savings Bank, son of billionaire real estate developer Seymour Milstein Christopher M. Jeffries (1972), real estate developer, former husband of Princess Yasmin Aga Khan Marc Porat (1972), entrepreneur in information technology and sustainable materials; co-founder of General Magic John R. Eckel Jr. (1973), founder, CEO and chairman of Copano Energy Finbarr O'Neill (1973), former CEO of J.D. Power Fred Seibert (1973), TV producer and first creative director of MTV Robert B.
== United Kingdom == The Public Health Laboratory Service (PHLS) was established as part of the National Health Service in 1946. An Emergency Public Health Laboratory Service was established in 1940 as a response to the threat of bacteriological warfare. There was originally a central laboratory at Colindale and a network of regional and local laboratories. By 1955 there were about 1000 staff. These laboratories were primarily preventive with an epidemiological focus. They were, however, in some places located with hospital laboratories which had a diagnostic focus. The PHLS was replaced by the Health Protection Agency in 2003; the HPA was disbanded and in its stead was constituted Public Health England, which later became the UK Health Security Agency in 2021.
==== Elsewhere ==== Phenazepam was classified as a narcotic in Finland in July 2014. Phenazepam is considered a narcotic in Norway, as per a March 23, 2010 Health Department addition to the Regular Narcotic List. In Russia, phenazepam is a controlled substance since March 22, 2021. In Estonia, phenazepam is a Schedule IV substance under the Narcotic Drugs and Psychotropic Substances Act. Schedule IV is the lowest classification of psychoactive substances in Estonia. It includes prescribable drugs, including other benzodiazepines.
==== Examples of metabolism-based interactions ==== An example of this is shown in the following table for the CYP1A2 enzyme, showing the substrates (drugs metabolized by this enzyme) and some inductors and inhibitors of its activity:
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.